Skip to search formSkip to main contentSkip to account menu

RAD 001

Known as: 001, RAD, RAD001 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

everolimus

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Chromogranin A and Its Fragments as Regulators of Small Intestinal Neuroendocrine Neoplasm Proliferation
Introduction Chromogranin A is a neuroendocrine secretory product and its loss is a feature of malignant NEN de-differentiation… 
2012
2012
RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
The mammalian target of rapamycin (mTOR) is regulated by oncogenic growth factor signals and plays a pivotal role in controlling… 
Highly Cited
2010
Highly Cited
2010
Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
8032 Background: Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or relapsed/refractory… 
Highly Cited
2010
Highly Cited
2010
Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer.
APC mutations cause activation of Wnt/beta-catenin signaling, which invariably leads to colorectal cancer. Similarly… 
2010
2010
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein.
Review
2009
Review
2009
Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)
Purpose: To assess the incidence and radiographic and clinical presentation of pneumonitis associated with the mammalian target… 
2008
2008
A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously…
8051 Background: R is an oral inhibitor of the mammalian target of rapamycin (mTOR) in clinical development as an anticancer… 
Highly Cited
2006
Highly Cited
2006
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Rapamycin and its derivatives are promising anticancer agents, but the exact mechanisms by which these drugs induce cell cycle… 
Review
2006
Review
2006
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Therapeutics that interfere with estrogen receptor function (antiestrogens, eg, tamoxifen; aromatase inhibitors, eg, letrozole… 
2000
2000
High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system.
A semi-automated solid-phase extraction (SPE) liquid chromatography/mass spectrometry (LC/MS) procedure was validated for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)